Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

Overview

A study to evaluate the safety and pharmacokinetics profile of different doses of AB103 administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled for an urgent surgical intervention as part of their standard of care.

Full Title of Study: “Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 2012

Detailed Description

A study to evaluate the safety and pharmacokinetics profile of different doses of AB103 administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled for an urgent surgical intervention as part of their standard of care. The primary study hypothesis is that AB-103 can be administered safely to the patients presenting with Necrotizing Soft Tissue Infections.

Secondary endpoints are efficacy by exploratory descriptive analyses of specific efficacy endpoints from three outcome domains to demonstrate treatment benefit of AB103 in comparison to placebo in patients with Necrotizing Soft Tissue Infections. The efficacy domains are:

1. Clinical status domain

2. Pharmacoeconomics domain

3. Systemic and local inflammatory biomarker domain

Interventions

  • Drug: AB103 0.25 mg/kg
    • Active
  • Drug: AB103 0.5 mg/kg
    • Active
  • Drug: NaCl 0.9%
    • Placebo

Arms, Groups and Cohorts

  • Active Comparator: AB103 0.25 mg/kg
  • Active Comparator: AB103 0.5 mg/kg
  • Placebo Comparator: NaCl 0.9%

Clinical Trial Outcome Measures

Primary Measures

  • Safety
    • Time Frame: 28 days
    • Vital Signs, Clinical laboratory parameters, Adverse Events, ECG
  • Pharmacokinetics
    • Time Frame: 1 day
    • Composite of pharmacokinetics parameters of AB103 at the following time points: prior to infusion, at mid infusion, end of infusion, and at 2, 5, 10, 20, 30, 60 and 120 minutes post infusion

Secondary Measures

  • Efficacy Clinical status
    • Time Frame: 28 days
    • Exploratory descriptive analyses of clinical parameters to demonstrate treatment benefit of AB103 in comparison to placebo in patients with Necrotizing Soft Tissue Infections. 1. Clinical end points: Time to normalization of systemic inflammatory signs (based on measurements of WBC and CRP) Resolution of organ dysfunction over time (by SOFA score) Time to last debridement/time to no significant progression of tissue necrosis Number of debridements through day 7
  • Efficacy Pharmacoeconomics domain
    • Time Frame: 28 Days
    • Exploratory descriptive analyses of pharmacoeconomic parameters to demonstrate treatment benefit of AB103 in comparison to placebo in patients with Necrotizing Soft Tissue Infections. 2. Pharmacoeconomics end points: Days in hospital Days in ICU / ICU free days Mechanical ventilation free days Vasopressor free days
  • Efficacy Systemic and local inflammatory biomarker
    • Time Frame: 7 Days
    • Exploratory descriptive analyses of systemic and local inflammatory biomarkers to demonstrate treatment benefit of AB103 in comparison to placebo in patients with Necrotizing Soft Tissue Infections. 3. Systemic and local inflammatory biomarkers end points: Systemic biomarkers Tissue biomarkers

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of NSTI due to bacterial infection (Necrotizing Fasciitis, Group A streptococcal infection or non group A streptococcal infection, Fournier's gangrene, Bacterial synergistic gangrene, Synergistic Necrotizing Cellulitis, Clostridial gas gangrene/ myonecrosis) that may be supported by specific signs and symptoms, e.g. tense edema outside area of compromised skin, pain disproportionate to appearance, skin discoloration, ecchymosis, blisters/bullae, necrosis, tense edema, crepitus and/or subcutaneous gas AND a decision for urgent surgical exploration and debridement;
  • Patient who did not receive the study drug prior to the surgery need to have a definite diagnosis of NSTI confirmed surgically (e.g. presence of necrotic tissue, thrombosed vessels in the subcutaneous tissue, lack of bleeding and "dishwater" (cloudy, thin, gray) fluid) in order to get the drug during or after operation;
  • IV drug administration within 6 hours from the clinical diagnosis and from the documented decision to have an urgent surgical exploration and debridement;
  • Signed and dated ICF as defined by the IRB and, if applicable, California Bill of Rights. By signing the ICF, the patient agrees to release any medical records pursuant to current Health Insurance Portability and Accountability Act (HIPAA) Guidelines. If patient is unable to comprehend or sign the ICF, patient's legally acceptable representative may sign the ICF;

Exclusion Criteria

  • Age < 18 years;
  • Weight > 150 Kg / 330 pounds;
  • Pregnant or lactating women; Female of childbearing potential, the patient must have a negative beta subunit hCG pregnancy test immediately prior to study entry (performed by urine or blood test, whichever is faster);
  • Patient who has been operated at least once for the current NSTI infection and had a curative deep tissue debridement (diagnostic surgery is allowed to enter into the study);
  • Known HIV infection with CD4 count < 200 cells/mm3 or < 14% of all lymphocytes;
  • Diabetic patients with below ankle infection;
  • Patients with overt peripheral vascular disease in the involved area – condition associated with ischemic ulcers and /or symptoms of inadequate vascular supply (e.g. intermittent claudication) where limb amputation is considered likely within 7 days;
  • Current status of: a. Mean arterial pressure < 50 mmHg and/or systolic blood pressure < 70 mmHg despite treatment with vasopressors and/or IV fluids or b. a patient with respiratory failure such that an SaO2 of 80% cannot be achieved or c. a patient with refractory coagulopathy (INR > 3) or d. thrombocytopenia (platelet count < 20,000) that does not partially correct with administration of appropriate factors, or e. likely severe neurological impairment secondary to cardiac arrest.
  • Patients with cardiac arrest requiring cardiopulmonary resuscitation within the past 30 days;
  • Patient is not expected to survive 30 days because of underlying medical condition, such as poorly controlled neoplasm (e.g. Stage III or IV cancer);
  • Any concurrent medical condition, which in the opinion of the investigator, may compromise their safety or the objectives of the study or the patient will not benefit from treatment, (e.g. end stage organ disease {CHF {NYHA class III-IV}, COPD {stage III-IV}, Liver dysfunction {Childs-Pugh class C}, Renal dysfunction {Dialysis}), immunosuppression, receiving or about to receive chemotherapy or known severe neutropenia < 1,000 cells/mm3;
  • Patients with Necrotizing Soft Tissue Infection post intra-abdominal operation;
  • Patient with burn wounds;
  • Patient or patient's family are not committed to aggressive management of the patient's condition, or the combination of necrotizing skin infection and underlying illness makes it unlikely that life support will be maintained;
  • Previous enrolment in an previous clinical trial involving investigational drug or a medical device within 30 days before provision of written informed consent for the study or within five half lives of the investigational drug, whichever is longer;

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Atox Bio Ltd
  • Provider of Information About this Clinical Study
    • Sponsor

Citations Reporting on Results

Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldawer LL, Demetriades D, Talving P, Schreiber M, Ham B, Cohen M, Opal S, Segalovich I, Maislin G, Kaempfer R, Shirvan A. A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial. JAMA Surg. 2014 Jun;149(6):528-36. doi: 10.1001/jamasurg.2013.4841.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.